Gyre Therapeutics (GYRE) Gross Profit (2020 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Gross Profit of $21.3 million for Q1 2026, up 0.6% year-over-year from $21.2 million in Q1 2025, and down 39.94% quarter-over-quarter from $35.5 million in Q4 2025.
Gyre Therapeutics (GYRE) Gross Profit (2020 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Gross Profit for 7 consecutive years, with $21.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Profit rose 0.6% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $111.3 million (up 14.93% YoY), while the FY2025 annual figure was $111.2 million, up 9.13% from the prior year.
- Gross Profit declined to $21.3 million in Q1 2026 per GYRE's latest filing, from $35.5 million in the prior quarter.
- Across five years, Gross Profit topped out at $97.5 million in Q4 2022 and bottomed at -$4000.0 in Q1 2022.
- Historically, Gross Profit has averaged $29.4 million across 5 years, with a median of $25.9 million in 2023.
- On a YoY basis, Gross Profit climbed as much as 595250.0% in 2023 and fell as far as 73.44% in 2023.
- Gyre Therapeutics' Gross Profit stood at $97.5 million in 2022, then slumped by 73.44% to $25.9 million in 2023, then climbed by 3.08% to $26.7 million in 2024, then soared by 32.8% to $35.5 million in 2025, then sank by 39.94% to $21.3 million in 2026.
- Business Quant data shows GYRE's Gross Profit at $21.3 million in Q1 2026, $35.5 million in Q4 2025, and $28.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.90 Mn |
| Jun 30, 2026 | 26.90 Mn |
| Mar 31, 2026 | 21.29 Mn |
| Mar 31, 2026 | 21.29 Mn |
| Dec 31, 2025 | 35.45 Mn |
| Dec 31, 2025 | 35.45 Mn |
| Sep 30, 2025 | 28.94 Mn |
| Sep 30, 2025 | 28.94 Mn |
| Jun 30, 2025 | 25.62 Mn |
| Jun 30, 2025 | 25.62 Mn |
| Mar 31, 2025 | 21.16 Mn |
| Mar 31, 2025 | 21.16 Mn |
| Dec 31, 2024 | 26.70 Mn |
| Dec 31, 2024 | 26.70 Mn |
| Sep 30, 2024 | 24.53 Mn |
| Sep 30, 2024 | 24.53 Mn |
| Jun 30, 2024 | 24.46 Mn |
| Jun 30, 2024 | 24.46 Mn |
| Mar 31, 2024 | 26.19 Mn |
| Mar 31, 2024 | 26.19 Mn |